TrialThe Journal of clinical endocrinology and metabolism2022

Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.

Xinru Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.